

**WE CLAIM:**

1. A bioavailable oral dosage form of loratadine comprising loratadine having an average particle size ranging from about 0.1 microns to about 15 microns and having a surface area ranging from between 1 and 2.5 m<sup>2</sup>/g.
2. The bioavailable oral dosage form of claim 1, wherein the particle size of loratadine is between about 1 micron to about 10 microns.
3. The bioavailable oral dosage form of claim 1, wherein the surface area of loratadine is between 1.25 and 2.0 m<sup>2</sup>/g.
4. The bioavailable oral dosage form of claim 1, wherein the drug is mixed with other pharmaceutically acceptable fillers, binders, and lubricants.
5. The bioavailable oral dosage form of claim 4, wherein the fillers used are selected from the group consisting of saccharides, polyhydric alcohols, celluloses, and cellulose ethers.
6. The bioavailable oral dosage form of claim 4, wherein the fillers are selected from the group consisting of lactose, dextrose, sucrose, microcrystalline celluloses, hydroxypropyl methyl cellulose, and mixtures thereof.
7. The bioavailable oral dosage form of claim 4, wherein the binders are selected from the group consisting of starch, polyvinylpyrrolidone, and gums.

8. The bioavailable oral dosage form of claim 4, wherein the lubricants are selected from the group consisting of talc, magnesium stearate, zinc stearate, tristearin, tripalmitin, polyethylene glycol, waxes, aerosil, and mixtures thereof.
9. The bioavailable oral dosage form of claim 1, wherein the dosage form is formulated as a tablet, capsule or suspension.
10. A process for the preparation of a bioavailable oral dosage form of loratadine comprising the step of milling said loratadine to reduce the particle size such that the average particle size ranges from about 0.1 microns to about 15 microns and the surface area ranges from between 1 and 2.5 m<sup>2</sup>/g.
11. The process as described in claim 10, wherein the particle size of loratadine is between about 1 micron to about 10 microns.
12. The process as described in claim 10, wherein the surface area of loratadine is between 1.25 and 2.0 m<sup>2</sup>/g.
13. The process as described in claim 10, wherein the milled drug is mixed with other pharmaceutically acceptable fillers, binders, and lubricants.
14. The process as described in claim 13, wherein the fillers used are selected from the group consisting of saccharides, polyhydric alcohols, celluloses, and cellulose ethers.
15. The process as described in claim 13, wherein the fillers are selected from the group consisting of lactose, dextrose, sucrose, micro-

crystalline celluloses, hydroxypropyl methyl cellulose, and mixtures thereof.

16. The process as described in claim 13, wherein the binders are selected from the group consisting of starch, polyvinylpyrrolidone, and gums.
17. The process as described in claim 13, wherein the lubricants are selected from the group consisting of talc, magnesium stearate, zinc stearate, tristearin, tripalmitin, polyethylene glycol, waxes, aerosil, and mixtures thereof.
18. The process as described in claim 10, wherein the dosage form is formulated as a tablet, capsule or suspension.